Medigene AG

MDG1

Company Profile

  • Business description

    Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

  • Contact

    Lochhamer Strasse 11
    Martinsried
    PlaneggBY82152
    DEU

    T: +49 892000330

    E: investor@medigene.com

    https://www.medigene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    87

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries7,561.70142.70-1.85%
CAC 406,890.92209.50-2.95%
DAX 4019,740.47539.79-2.66%
Dow JONES (US)37,634.5711.02-0.03%
FTSE 1007,688.55221.98-2.81%
HKSE20,264.49136.810.68%
NASDAQ15,471.87203.961.34%
Nikkei 22531,714.031,298.55-3.93%
NZX 50 Index11,806.5584.89-0.71%
S&P 5005,000.2817.510.35%
S&P/ASX 2007,375.00135.00-1.80%
SSE Composite Index3,186.8141.261.31%

Market Movers